The Cell Shuttle enables end-to-end automation of the processes needed to create individualized cell therapies, including chimeric antigen receptor (CAR) T therapies. The shuttle is a modular tool consisting of hardware, software, robotics, and consumables with the capability of producing 10 patient doses simultaneously. The single platform allows preclinical development efforts to easily transfer to the clinical environment.
Cellares estimates that the Cell Shuttle can lower costs by up to 75% and shorten time to market by as much as one to two years.
The series B financing was led by new investor Decheng Capital and co-led by existing investor Eclipse Ventures.
Cellares' scalable factory-in-a-box. Image courtesy of Cellares.
Copyright © 2021 scienceboard.net